[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2010002909A - Metodo de tratamiento de pacientes de hepatitis c. - Google Patents

Metodo de tratamiento de pacientes de hepatitis c.

Info

Publication number
MX2010002909A
MX2010002909A MX2010002909A MX2010002909A MX2010002909A MX 2010002909 A MX2010002909 A MX 2010002909A MX 2010002909 A MX2010002909 A MX 2010002909A MX 2010002909 A MX2010002909 A MX 2010002909A MX 2010002909 A MX2010002909 A MX 2010002909A
Authority
MX
Mexico
Prior art keywords
patients
treatment
treating hepatitis
naã
hcv infection
Prior art date
Application number
MX2010002909A
Other languages
English (en)
Inventor
Janice K Albrecht
Clifford A Brass
Ii Robert Orville Ralston
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010002909(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010002909A publication Critical patent/MX2010002909A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Esta solicitud describe un método novedoso de identificación de pacientes, entre pacientes nuevos en el tratamiento que padecen infección de VHC, que son susceptibles de tratamiento con un inhibidor de proteasa; la solicitud también describe un método de tratamiento de pacientes nuevos en el tratamiento, pacientes no respondedores y pacientes en recaída que padecen una infección de VHC.
MX2010002909A 2007-09-14 2008-09-11 Metodo de tratamiento de pacientes de hepatitis c. MX2010002909A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99375307P 2007-09-14 2007-09-14
US99876207P 2007-10-12 2007-10-12
US149407P 2007-10-30 2007-10-30
PCT/US2008/010626 WO2009038663A1 (en) 2007-09-14 2008-09-11 Method of treating hepatitis c patients

Publications (1)

Publication Number Publication Date
MX2010002909A true MX2010002909A (es) 2010-03-30

Family

ID=40262964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002909A MX2010002909A (es) 2007-09-14 2008-09-11 Metodo de tratamiento de pacientes de hepatitis c.

Country Status (18)

Country Link
US (1) US20100226885A1 (es)
EP (2) EP2489369A1 (es)
JP (1) JP2010539165A (es)
CN (1) CN101883590A (es)
AT (1) ATE519503T1 (es)
AU (1) AU2008301981A1 (es)
CA (1) CA2699280A1 (es)
CY (1) CY1112116T1 (es)
DK (1) DK2061513T3 (es)
ES (1) ES2369321T3 (es)
HK (1) HK1129315A1 (es)
HR (1) HRP20110637T1 (es)
MX (1) MX2010002909A (es)
NZ (1) NZ583825A (es)
PL (1) PL2061513T3 (es)
PT (1) PT2061513E (es)
SI (1) SI2061513T1 (es)
WO (1) WO2009038663A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2704570A4 (en) * 2011-05-04 2015-02-18 Merck Sharp & Dohme ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
ES2659216T5 (es) 2011-09-16 2021-06-09 Gilead Pharmasset Llc Métodos para el tratamiento del VHC
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
PT107925A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2012332827A1 (en) 2011-10-31 2014-05-15 Gilead Pharmasset Llc Methods and compositions for treating hepatitis C virus
BR112014012739A8 (pt) * 2011-11-29 2017-06-20 Gilead Pharmasset Llc composições e métodos para o tratamento do vírus da hepatite c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2809334A4 (en) 2012-02-01 2015-06-24 Abbvie Inc ONCE DAILY TREATMENT OF HEPATITIS C WITH RIBAVIRIN AND TARIBAVIRIN
CN105748499B (zh) 2013-01-31 2018-12-28 吉利德制药有限责任公司 两个抗病毒化合物的联用制剂
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2157000A (en) * 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
PE20001548A1 (es) * 1999-03-02 2001-01-16 Schering Corp Uso de interferon alfa pegilado para el tratamiento de vih-1
KR100939155B1 (ko) * 2000-07-21 2010-01-28 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제 억제제로서의신규한 펩티드
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CN101076516A (zh) * 2004-02-27 2007-11-21 先灵公司 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物
WO2006016930A2 (en) * 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
EP1981524A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
AU2009256623A1 (en) * 2008-06-10 2009-12-17 Janssen Pharmaceutica Nv Telaprevir dosing regimen

Also Published As

Publication number Publication date
WO2009038663A1 (en) 2009-03-26
DK2061513T3 (da) 2011-11-21
CY1112116T1 (el) 2015-11-04
CA2699280A1 (en) 2009-03-26
PT2061513E (pt) 2011-10-17
ATE519503T1 (de) 2011-08-15
HK1129315A1 (en) 2009-11-27
ES2369321T3 (es) 2011-11-29
NZ583825A (en) 2012-06-29
CN101883590A (zh) 2010-11-10
US20100226885A1 (en) 2010-09-09
EP2061513B1 (en) 2011-08-10
PL2061513T3 (pl) 2011-12-30
EP2489369A1 (en) 2012-08-22
SI2061513T1 (sl) 2011-11-30
AU2008301981A1 (en) 2009-03-26
JP2010539165A (ja) 2010-12-16
HRP20110637T1 (hr) 2011-10-31
EP2061513A1 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
MX2010002909A (es) Metodo de tratamiento de pacientes de hepatitis c.
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
MY165570A (en) Inhibitors of poly (adp-ribose) polymerase
GEP20084545B (en) Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection
TW200714283A (en) Method and composition for treating peripheral vascular diseases
SG10201406297TA (en) Methods for treating progressive multiple sclerosis
SG179488A1 (en) Virus like particle purification
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
MX2020009703A (es) Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
DK1505990T3 (da) Fremgangsmåder til behandling af hepatitis
GEP20166426B (en) Pirfenidone therapy and inducers of cytochrome p450
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
MX2009007053A (es) Inhibidores de poli (adp-ribosa) polimerasa.
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
TW200507840A (en) Method of treating multiple myeloma
WO2008092099A3 (en) Compositions and methods for treating hematopoietic malignancies
MY152546A (en) A non-reusable circumcision clamp
MX2009003022A (es) Composiciones y metodos para tratar picaduras de medusa.
UA88655C2 (ru) S-миртазапин для лечения прилива крови
MY166063A (en) Intravenous antiviral treatments
WO2008033368A3 (en) Boroproline compound and cytokine combination therapy
UA29556U (ru) Способ лечения больных острыми вирусными менингитами
UA35880U (ru) Способ лечения острого токсико-аллергического гепатита
UA34823U (ru) Способ лечения больных острым вирусным гепатитом в
UA29548U (en) Method for treating osteoarthrosis

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: QLT INC.

FA Abandonment or withdrawal